Jian-ming Huang
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
Journal: Gynecologic oncology
Published: September 29, 2022
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer.
Journal: Journal of ovarian research
Published: June 11, 2022
The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Journal: Journal of ovarian research
Published: February 13, 2021
One-stage posterior approach for treating multilevel noncontiguous thoracic and lumbar spinal tuberculosis.
Journal: Postgraduate medicine
Published: December 27, 2018
TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Journal: Gynecologic oncology
Published: November 14, 2013
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Journal: Scientific reports
Published: July 15, 2013
Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.
Journal: Journal of translational medicine
Published: January 12, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026